Cho J, et al. - In this phase II study, researchers tested the effectiveness and safety of pembrolizumab in patients with thymic epithelial tumor (TET). Eligibility criteria included patients with histologically confirmed TET whose disease progressed after at least one line of platinum-based chemotherapy. Of the 33 enrolled patients, 26 had thymic carcinoma and 7 had thymoma. Pembrolizumab demonstrated that antitumor activity is encouraging in patients with advanced TET. Dyspnea, pain in the chest wall, anorexia and fatigue were the most common adverse events of any grade.